Using rTMS to improve symptoms of Parkinson's Disease
A Multicenter Clinical Study of rTMS for Parkinson's Disease
This study is testing if adding a special brain treatment called rTMS to regular care can help improve both movement and thinking problems in people with Parkinson's Disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 30 Years to 80 Years |
| Sex | All |
| Sponsor | Affiliated Hospital of Nantong University Academic / other |
| Locations | 1 site (Nantong, Jiangsu) |
| Trial ID | NCT06009471 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in improving both motor and non-motor symptoms in patients with Parkinson's Disease. A total of 200 participants will be enrolled and randomly assigned to either a control group receiving conventional treatment or an observation group receiving conventional treatment plus rTMS over a treatment cycle of four weeks. Participants will be assessed using various scales, including the Unified Parkinson's Disease Rating Scale (UPDRS) and the Montreal Cognitive Assessment Scale (MoCA), to measure changes in their condition and quality of life. Follow-up evaluations will occur at multiple time points to monitor progress and any adverse events.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 30 to 80 with mild cognitive impairment and a Hoehn-Yahr classification of 1 to 2.
Not a fit: Patients with severe cognitive disorders, serious mental health issues, or significant physical dysfunctions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life for patients with Parkinson's Disease by improving their motor and cognitive functions.
How similar studies have performed: Previous studies have shown promising results with rTMS in treating various neurological conditions, suggesting potential success for this approach in Parkinson's Disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hoehn-YAHR classification is between 1 and 2； * Have a primary school education or above and can read the scale used in this study; * MoCA score between 20 and 24, mild cognitive impairment ; * Aged between 30 and 80, regardless of gender； * Voluntarily participate and sign informed consent. Exclusion Criteria: * patients with cerebrovascular accident, craniocerebral injury and other diseases affecting muscle tension; * patients with serious mental disorders and cognitive disorders who cannot cooperate with assessment; * patients with severe liver, kidney, heart dysfunction and severe physical disorders; * Implanted devices such as pacemakers are installed inside the body; * drug-induced Parkinson's syndrome or Parkinson's superposition syndrome; * Have a history of epilepsy; * Women during pregnancy and breastfeeding.
Where this trial is running
Nantong, Jiangsu
- rTMS — Nantong, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Aisong Guo
- Email: guoasg@ntu.edu.cn
- Phone: 15851300188
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.